Clinical Trial Update: Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

Phase 2a trial of VX-147 in adults with APOL1-mediated focal segmental glomerulosclerosis has completed, and results were posted in July 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• VX-147 (VX-147)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Glomerulosclerosis, Focal Segmental | Phase 2 | Status: COMPLETED | Results posted: 2023-07-10